Coumaric Acid

Coumaric Acid

SCHEMBL434720

O=C(O)/C=C\c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 1.00
TYR P14679 3/20 1.00
AKR1B10 O60218 3/20 1.00
AKR1B1 P15121 3/20 1.00
CA12 O43570 3/20 1.00
CA1 P00915 3/20 1.00
CA2 P00918 3/20 1.00
CA7 P43166 3/20 1.00
CA9 Q16790 3/20 1.00
CA14 Q9ULX7 3/20 1.00
ESR2 Q92731 3/20 1.00
HCAR2 Q8TDS4 2/20 1.00
PKM P14618 2/20 1.00
CA3 P07451 2/20 1.00
CA4 P22748 2/20 1.00
CA6 P23280 2/20 1.00
DPP4 P27487 2/20 1.00
CA5A P35218 2/20 1.00
CA5B Q9Y2D0 2/20 1.00
F3 P13726 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coumaric Acid SCHEMBL6333102 1.00 ESR1 (1.00) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL39106 1.00 ESR1 (1.00) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL6333097 1.00 ESR1 (1.00) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL20702657 1.00 ESR1 (1.00) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL43601 1.00 ESR1 (1.00) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL6328280 0.98 ESR1 (0.95) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL1221500 0.98 ESR1 (0.95) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL7871865 0.98 ESR1 (0.95) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL7040450 0.98 ESR1 (0.95) ESR1TYRAKR1B10AKR1B1CA12
Coumaric Acid SCHEMBL5606477 0.98 ESR1 (0.95) ESR1TYRAKR1B10AKR1B1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024033288-A1 SALICIN DERIVATIVES AS INHIBITORS OF SGLT2 Société des Produits Nestlé S.A. (CH) 2024-02-15 WO claimed
CN-111562340-B Method for rapidly carrying out species analysis and content determination on anthocyanin in tomato fruits 中国农业科学院蔬菜花卉研究所 2023-02-07 CN claimed
CN-107753542-B South American wedelia chinensis antioxidant extract and preparation method and application thereof 海南师范大学 2021-05-07 CN claimed
US-20110183929-A1 STANDARDIZED EXTRACT AND FRACTION FROM HANCORNIA SPECIOSA LEAVES AND PHARMACEUTICAL COMPOSITION THEREOF UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) 2011-07-28 US claimed
EP-2335711-A2 EXTRACT OF HANCORNIA SPECIOSA AND PHARMACEUTICAL COMPOSITION THEREOF Universidade Federal de Minas Gerais-UFMG (BR) 2011-06-22 EP claimed
CN-1247606-C Two (2)-4-hydroxycinnamic acid glycosides and their application RES INST OF OCEAN OF THE SOUTH (CN) 2006-03-29 CN claimed
CN-1515580-A Two (2)-4-hydroxycinnamic acid glycosides and their application 中国科学院南海海洋研究所 2004-07-28 CN claimed
US-20260101892-A1 METHOD TO INHIBIT PROLIFERATION OF A PHYTOPATHOGEN ON PLANTS AND COMPOSITIONS USED FOR THIS PURPOSE CYSBIO APS (DK) 2026-04-16 US disclosed
US-20260076954-A1 COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELLS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2026-03-19 US disclosed
US-12544368-B2 Compositions and methods for reducing cancer stem cells THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2026-02-10 US disclosed
US-20250351855-A1 TASTE OF CONSUMABLES THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) 2025-11-20 US disclosed
US-12370232-B2 Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition Poly Gain Pte Ltd (SG) 2025-07-29 US disclosed
CN-119968127-A Animal food compositions with improved palatability and customizable properties and methods of making the same 玛氏公司 2025-05-09 CN disclosed
US-4681954-A 7,8,9,10-tetrahydro-6-oxo-6H-dibenzo(b,d)pyranyloxy-propanes PENNWALT CORPORATION (US) 1987-07-21 US disclosed
EP-0221293-A1 7,8,9,10-Tetrahydro-6-oxo-6H-dibenzo[b,d]pyranyloxy-propanes PENNWALT CORPORATION (US) 1987-05-13 EP disclosed
EP-0039472-B1 RADIATION-CROSSLINKABLE POLYESTERS AND POLYESTERETHERS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1984-08-15 EP disclosed
US-4343888-A Use of radiation crosslinkable polyesters and polyesterethers in printing plates E. I. DU PONT DE NEMOURS AND COMPANY (US) 1982-08-10 US disclosed
EP-0039472-A1 Radiation-crosslinkable polyesters and polyesterethers E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-11-11 EP disclosed
US-4284710-A FROM DIEPOXIDE AND AROMATIC UNSATURATED DICARBOXYLIC ACID OR HYDROXY ACID E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-08-18 US disclosed
US-4247597-A Electroscopic carrier particles having a carboxylic acid surface treatment PITNEY BOWES, INC. (US) 1981-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260101892-A1 METHOD TO INHIBIT PROLIFERATION OF A PHYTOPATHOGEN ON PLANTS AND COMPOSITIONS USED FOR THIS PURPOSE HAAO, NOTUM, WEE1 ESR1 4318/4885TYR 23/4885AKR1B10 3264/4885
US-12544368-B2 Compositions and methods for reducing cancer stem cells MCL1, BCL9, MYADM ESR1 1189/4885TYR 4081/4885AKR1B10 1621/4885
US-20260076954-A1 COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELLS MCL1, FLT3, MYADM ESR1 666/4885TYR 3984/4885AKR1B10 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.